
0.724 Delayed Data As of Mar 24 | ![]() Today’s Change | 0.71 Today|||52-Week Range 6.27 | -67.96% Year-to-Date |
The 7 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 3.00, with a high estimate of 6.00 and a low estimate of 1.50. The median estimate represents a +314.36% increase from the last price of 0.72.
The current consensus among 11 polled investment analysts is to Hold stock in Nektar Therapeutics. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.